Legend Biotech remains a buy as Carvykti's earlier-line use drives superior efficacy, safety, and manufacturing success, signaling a structural shift in multiple myeloma therapy. Recent CARTITUDE-4 ...

Initial findings show that the therapy reduced or eliminated disease signs in all recipients, sparking hopes that the treatment might be competitive with “ex vivo” medicines like Novartis’ Kymriah.

US biotech Legend Biotech (NASDAQ: LEGN) has reported early first-in-human data for LB2501, its investigational in vivo CAR-T therapy for relapsed or refractory B-cell non-Hodgkin lymphoma, triggering ...

Legend Biotech (LGND) added ~26% in the morning hours on Tuesday after announcing initial results from an early-stage trial for LB2501, its in vivo CAR-T cell therapy targeting B-cell non-Hodgkin ...

Promising Phase 1 data for LB2501, a potential first‑in‑class CD19/CD20 dual‑targeting in vivo CAR-T therapy, as an off-the-shelf, single-infusion treatment for B‑cell malignancies An ORR of 100% (6/6 ...

LB2102 demonstrated a manageable safety profile and encouraging clinical activity in solid tumors among heavily pretreated patients Responses observed at higher dose levels of LB2102 with an ORR of 28 ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

It appears I Am Legend 2 is moving forward at Warner Bros., with reports indicating Transformers: Rise of the Beasts director Steven Caple Jr. is officially developing the sequel. I Am Legend is a ...

Italy awarded a €211 million ($249 million) grant to a company seeking to speed up processing at artificial intelligence data centers as part of a bid to support local startups. 2D Photonics Group’s ...